News|Videos|November 12, 2025

Reducing C difficile Incidence Rates

Fact checked by: Justin Mancini

During National C difficile Awareness Month, the Peggy Lillis Foundation is working toward greater awareness about prescribing practices as well as cleaning methods that can prevent infections.

Clostridioides difficile continues to be the leading cause of health care–associated infections in the United States, with over 400,000 infections and an estimated 29,300 associated deaths annually.1 Although the incidence rates have trended downward slightly, the burden of disease continues to loom large.

November is National C difficile Awareness Month, and the Peggy Lillis Foundation (PLF) for C diff Education & Advocacy is the premier C difficile organization dedicated to lending support and education to patients and caregivers.

PLF Cofounder and CEO Christian John Lillis says they are chipping away at awareness about the infection. “Since we launched this, our C difficile awareness campaign, 6 years ago, we have seen a 6-point increase in C difficile awareness,” Lillis said. “So we went from 40% of Americans having heard of C difficile to 46%—hopefully we crack 50%. I'd really like there to be more than half…. Six percent doesn't sound like a big number, but in a country the size of the US, we're talking about 20 million people who have learned about C difficile in the past 6 years.”

PLF has a full slate of activities this month directed at education. For example, tonight, PLF will offer its webinar "Household Hygiene Practices for People With C diff and Caregivers," which will be led by Cathy Egan, PhD, professor at Conestoga College in Kitchener, Ontario, Canada. She will provide evidence-based guidance on safe home-cleaning practices during and after a C difficile infection. To sign up for tonight’s event, go here.

Additionally, the organization will conclude the month with its second annual Scientific Symposium on November 21—a full-day virtual event featuring experts discussing the latest developments in C difficile treatment, epidemiology, and prevention. To learn more about this event, go here.

Lillis says C difficile can be prevented, and awareness about prescribing practices is one way to do so. “There have been a few studies that have shown that you can reduce it by reducing the use of medically unnecessary antibiotics,” he said. “And also being picky about what class of antibiotics you use, you can reduce C difficile rates in hospitals by up to 80%.... The more you know about C difficile, the more you can be a partner in your care and in the decision-making.”

Reference
1. Guh AY, Mu Y, Winston LG, et al; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320-1330. doi:10.1056/NEJMoa1910215


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.